Our Mission

The mission of PPMI is to identify one or more biomarkers of Parkinson’s disease progression. The discovery of a biomarker is a critical step in the development of new and better treatments for PD. This study is being sponsored by The Michael J. Fox Foundation for Parkinson's Research.

PPMI Enrollment Status

Genetic Cohort Participants
Enrollment Goal: 600

Genetic Registry Participants
Enrollment Goal: ~600

De Novo PD Participants
Enrollment: 423

Control Participants
Enrollment: 196

Subjects with SWEDD
Enrollment: 64

Prodromal Participants
Enrollment: 65

Last Update: July 28, 2015


More about study cohorts >


Welcome to the Parkinson’s Progression Markers Initiative (PPMI), a landmark observational clinical study to comprehensively evaluate cohorts of significant interest using advanced imaging, biologic sampling and clinical and behavioral assessments to identify biomarkers of Parkinson’s disease progression.

PPMI is taking place at clinical sites in the United States, Europe, Israel, and Australia. Data and samples acquired from study participants will enable the development of a comprehensive Parkinson’s database and biorepository, which is currently available to the scientific community to conduct field-changing research.

PPMI is made possible by the concerted efforts of a number of collaborators. This study is sponsored by The Michael J. Fox Foundation for Parkinson’s Research.

Learn more about Who We Are.


Diffusion Tensor Imaging Reflects Degree of Motor Symptoms

In a recent publication in Movement Disorders, Zhang, et al. used PPMI data and found that diffusion tensor imaging (DTI) detected neural fiber abnormalities in people with Parkinson’s disease (PD) and that the degree of deviation from normal neural fiber integrity is associated with the severity of motor symptoms in patients.

PPMI Participating in Upcoming Datathon

The tranSMART Foundation is hosting the Cross Neurodegenerative Diseases Datathon June 30 – July 2. Scientists will use the tranSMART Platform to perform analyses across multiple public datasets in the neurodegenerative disease field, including PPMI, BioFIND, LRRK2, ADNI, and GEO PD.

Biospecimen Analysis Call for Participants Posted

Dr. Mollenhauer: “[Cerebrospinal fluid] bears the possibility to reflect the underlying biology of the disease process.” Find out what makes the PPMI biospecimens, like cerebrospinal fluid, so important to finding progression markers for PD.

New Feature: Subject Visit Tables

The Study Cohorts page has been updated to give researchers a view of the visit data available for each cohort.

PPMI at MDS 2015

PPMI is excited to announce that several presentations at the 19th International Congress of Parkinson’s Disease and Movement Disorders (MDS) will feature PPMI data. View the PPMI-related abstracts for this congress happening in San Diego, California on June 14-18.

Learn More